Amprenavir: A new human immunodeficiency virus type 1 protease inhibitor

Clinical Therapeutics

Volumn 22, Issue 5, 2000, Pages 549-572

  Fung, Horatio B ^a   Kirschenbaum, Harold L ^b   Hameed, Rizwanullah ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b LONG ISLAND UNIVERSITY   (United States)

^c KINGSBROOK JEWISH MEDICAL CENTER   (United States)

Author keywords

AIDS; Amprenavir; Human immunodeficiency virus (HIV); Protease inhibitor

Indexed keywords

ABACAVIR; ACETAZOLAMIDE; AMITRIPTYLINE; AMPRENAVIR; CLARITHROMYCIN; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; IMIPRAMINE; INDINAVIR; KETOCONAZOLE; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PETHIDINE; PROBENECID; PROPRANOLOL; PROTEINASE INHIBITOR; RALURIDINE; RIFABUTIN; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; SULFONAMIDE; SULFONYLUREA DERIVATIVE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; FOOD DRUG INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; METABOLIC DISORDER; PRACTICE GUIDELINE; REVIEW; TREATMENT PLANNING;

EID: 0033947226     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)80044-2     Document Type: Article

References (68)

1. 1. Boden D, Markowitz M. Resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother. 1998;42:2775-2783.
2. 2. Mouton P, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centers. AIDS. 1997;11:F101-F105.
3. 3. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
4. 4. Flexner C. HIV-protease inhibitors. N Engl J Med. 1998;338:1281-1292.
5. 5. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Rockville, Md: HIV/AIDS Treatment Information Service; 2000. Available at: http://www.hivatis.org. Accessed February 2, 2000.
6. 6. Kim EE, Baker CT, Dwyer MD, et al. Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme. J Am Chem Soc. 1995;117:1181-1182.
7. 7. Agenerase™ [package insert]. Cambridge, Mass: Vertex Pharmaceuticals Inc; 1999.
8. 8. Livingston DJ, Pazhanisamy S, Porter DJT, et al. Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy. J Infect Dis. 1995;172:1238-1245.
9. 9. St. Clair MH, Millard J, Rooney J, et al. In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents. Antiviral Res. 1996; 29:53-56.
10. 10. MacKichan JJ. Influence of protein binding and use of unbound (free) drug concentrations. In: Evans WE, Schentag JJ, Jusko WJ, Kelling MV, eds. Applied Pharmacokinetics. 3rd ed. Vancouver, Canada: Applied Therapeutics Inc; 1997:5-6.
11. 1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: A comparative study with other relevant HIV protease inhibitors. J Infect Dis. 1997;175:1063-1070.
12. 1-acid glycoprotein concentration on the antiviral efficacy of human immunodeficiency virus protease inhibitors. J Infect Dis. 1999;180:1833-1837.
13. 13. Sadler B, Gillotin C, Lou Y, Stien D. Effect of demographic laboratory and clinical covariates on the pharmacokinetics of amprenavir. In: Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, Ill. Abstract 375.
14. 14. Sadler BM, Hanson CD, Chittick CE, et al. Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor following oral administration of single doses to HIV-infected adults. Antimicrob Agents Chemother. 1999;43: 1686-1692.
15. 15. Decker CJ, Laitinen LM, Bridson GW, et al. Metabolism of amprenavir in liver microsomes: Role of CYP3A4 inhibition for drug interactions. J Pharm Sci. 1998;87: 803-807.
16. 16. Polli JW, Jarrett JL, Studenberg SD, et al. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharmacol Res. 1999; 16:1206-1212.
17. 17. Murphy R, Currier J, Gerber J, et al. Antiviral activity and pharmacokinetics of amprenavir with or without zidovudine/ lamivudine in the cerebral spinal fluid of HIV-infected adults. In: Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco, Calif. Abstract 314.
18. 18. Veronese L, Rautureau J, Sadler BM, et al. A study to compare the pharmacokinetics of a single oral 600-mg dose of amprenavir in healthy volunteers and patients with cirrhosis. In: Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26-29, 1999; San Francisco, Calif. Abstract 326.
19. 19. Richman DD. New strategies to combat HIV drug resistance. Hosp Practice. 1996; 31:47-58.
20. 20. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet. 1997;349:1086-1092.
21. 21. Partaledis JA, Yamaguchi K, Tisdale M, et al. In vitro selection and characterization of human immunodeficiency virus type 1 isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J Virol. 1995; 69:5228-5235.
22. 22. Nair AC, Miertus S, Tossi A, Romeo D. A computational study of the resistance of HIV-1 aspartic protease to the inhibitors ABT-538 and VX-478 and design of new analogues. Biochem Biophys Res Commun. 1998;242:545-551.
23. 23. Pazhanisamy S, Partaledis JA, Rao BG, Livingston DJ. In vitro selection and characterization of VX-478 resistant HIV-1 variants. Adv Exp Med Biol. 1998;436: 75-83.
24. 24. Tisdale M, Myers RE, Snowden W. Genotypic and phenoty pic analysis of HIV from patients on ZDV/3TC/amprenavir combination therapy. In: Abstracts of the 12th World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland. Abstract 32312.
25. 25. Maguire MF, Klein AP, Tisdale M, Snowden W. An alternative route to amprenavir resistance involves the V32I and I47V protease substitutions. In: Abstracts of the 7th European Conference on Clinical Aspects and Treatment of HIV-Infection; October 23-27, 1999; Lisbon, Portugal. Abstract 383.
26. 26. Schmidt B. Cross resistance to amprenavir in PI-treated patients. In: Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco, Calif. Abstract 726.
27. 27. Craig C, Race E, Sheldon J, et al. HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy. AIDS. 1998;12:1611-1618.
28. 28. Calvez V, Tamalet C, Molina JM, et al. Amprenavir shows less protease inhibitor cross resistance as compared with other protease inhibitors in a multiexperienced HIV cohort. In: Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26-29, 1999; San Francisco, Calif. Abstract 442.
29. 29. Race E, Dam E, Obry V, et al. Analysis of HIV cross resistance to protease inhibitors using a rapid single cycle recombinant virus assay for patients failing on combination therapies. AIDS. 1999;13:2061-2068.
30. 3. In: Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 15-18, 1996; New Orleans, La. Abstract LB07a.
31. 31. Haubrich R, Thompson M, Schooley R, et al. A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience, amprenavir PROAB2002 study team. AIDS. 1999;13:2411-2420.
32. 32. Kinloch S, Janossy G, Phillips A, et al. HAART (3TC/ZDV/abacavir/amprenavir) during primary HIV infection is associated with a sharp viremia decline and increase in IL-2 synthetic capacity. In: Abstracts of the 7th European Conference on Clinical Aspects and Treatment of HIV-Infection; October 23-27, 1999; Lisbon, Portugal. Abstract 131.
33. 33. Hoen B, Kinloch S, Janossy G, et al. Preliminary results: Quadruple HAART (3TC/ZDV/abacavir/amprenavir) initiated during primary HIV infection is associated with a sharp viremia decrease and increase in CD4 response. In: Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26-29, 1999; San Francisco, Calif. Abstract 685.
34. 34. Cooper D, Perrin L, Kinloch S, et al. Intervention with quadruple HAART (combivir/abacavir/amprenavir) during primary HIV-1 infection is associated with rapid viremia clearance and decrease of immune activation. In: Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco, Calif. Abstract 552.
35. 35. Goodgame J, Hanson C, Vafidis I, et al. Amprenavir/3TC/ZDV exerts durable antiviral activity in HIV-1 infected antiretroviral therapy-naïve subjects through 48 weeks of therapy. In: Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26-29, 1999; San Francisco, Calif. Abstract 509.
36. 3 and plasma HIV-1 RNA >5000 copies/mL. In: Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, Ill. Abstract 626.
37. 37. Rizzardi GP, Bart PA, Chapuis A, et al. Quantitative normalization of CD4 T cells in blood and lymph nodes of HIV-1-infected therapy naïve adults at early stage of chronic infection treated with abacavir plus amprenavir. In: Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26-29, 1999; San Francisco, Calif. Abstract 1822.
38. 38. Rizzardi GP, Bart PA, Chapuis A, et al. Immunologic and virologic responses after long-term HAART therapy in HIV-1 infected therapy-naïve adults at early stage of chronic infection. In: Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco, Calif. Abstract 336.
39. 39. Mellors J, Lederman M, Haas D, et al. Durable activity of ziagen combined with protease inhibitors in therapy naïve adults. In: Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, Ill. Abstract 625.
40. 40. Murphy RL, Gulick RM, DeGruttola V, et al. Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. J Infect Dis. 1999;179:808-816.
41. 41. Kost R, Cao Y, Zhang L, et al. Potent durable combination therapy with abacavir, amprenavir and ZDV/3TC in subjects acutely and chronically infected with HIV-1. In: Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, Ill. Abstract 639.
42. 42. Tisdale M, Myers RE, Maschera B, et al. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother. 1995;39:1704-1710.
43. 43. Kaul DR, Cinti SK, Carver PL, Hazanjian PH. HIV protease inhibitors: Advances in therapy and adverse reactions including metabolic complications. Pharmacotherapy. 1999;19:281-298.
44. 44. Eron J, Haubrich R, Richman D, et al. Preliminary assessment of 141W94 in combination with other protease inhibitors. In: Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 6.
45. 45. Data on file. Research Triangle Park, NC: Glaxo Wellcome Inc.
46. 46. Ait-Khaled M, Rakik A, Thomas D, et al. HIV-1 baseline genotype/phenotype and virological response following salvage therapy with ziagen, amprenavir and sustiva. In: Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, Ill. Abstract 133.
47. 47. Blanche S, Fetter A, Cox H, et al. A phase II study of amprenavir in antiretroviral-experienced children with HIV-infection. In: Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco, Calif. Abstract 695.
48. 48. Yogev R, Church J, Flynn P, et al. Pediatric trial of combination therapy including the protease inhibitor amprenavir. In: Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, Ill. Abstract 430.
49. 49. Church J, Rathore M, Rubio T, et al. A phase III study of amprenavir in protease-inhibitor naïve and experienced HIV-infected children and adolescents. In: Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco, Calif. Abstract 693.
50. 50. Struble K, Piscitelli SC. Syndromes of abnormal fat redistribution and metabolic complications in HIV-infected patients. Am J Health Syst Pharm. 1999;56:2343-2348.
51. 51. Adkins JC, Faulds D. Amprenavir. Drugs. 1998;55:837-842.
52. 52. Pedneault L, Fetter A, Hanson C, et al. Amprenavir: Review of overall safety profile. In: Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, Ill. Abstract 386.
53. 53. Fetter A, Nacci J, Yeo J, et al. Tolerability profile of amprenavir in combination with various NRTIs. In: Abstracts of the 7th European Conference on Clinical Aspects and Treatment of HIV-Infection; October 23-27, 1999; Lisbon, Portugal. Abstract 813.
54. 54. Schooley RT. Long-term immunologic effects and side effects of successful antiretroviral therapy. Clin Infect Dis. 1999; 29:12-18.
55. 55. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1 protease inhibitor associated peripheral lipodystrophy hyperlipidemia and insulin resistance. Lancet. 1998;351:1881-1883.
56. 56. Lenhard JM, Weiel JE, Paulik MA, et al. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. In: Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, Ill. Abstract 666.
57. 57. Lenhard JM, Weiel JE, Paulik MA, et al. Indinavir enhances retinoic acid signaling: Nelfinavir, saquinavir and ritonavir inhibit retinoid effects in vitro. In: Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, Ill. Abstract 665.
58. 58. Weiel J, Croom D, Furfine E, Lenhard J. Influence of diet on metabolic abnormalities in mice treated with HIV protease inhibitors. In: Abstracts of the 7th European Conference on Clinical Aspects and Treat ment of HIV-Infection; October 23-27, 1999; Lisbon, Portugal. Abstract 317.
59. 59. Fetter A, Nacci P, Lenhard J, et al. Fat distribution and retinoid-like symptoms are infrequent in NRT1-experienced subjects treated with amprenavir. In: Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco, Calif. Abstract 18.
60. 60. Polk RE, Crouch MA, Israel DS, et al. Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men. Pharmacotherapy. 1999;19:1378-1384.
61. 61. Barry M, Mulcahy F, Merry C, et al. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet. 1999;36:289-304.
62. 62. Michalets EL. Update: Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy. 1998;18:84-112.
63. 63. Gotzkowsky SK, Weidler J, Tonkin J, et al. Decrease in cytochrome P450 activity in HIV disease. In: Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26-29, 1999; San Francisco, Calif. Abstract 656.
64. 64. Sadler B, Gillotin C, Chittick CE, Symonds WT. Pharmacokinetic drug in teractions with amprenavir. In: Abstracts of the 12th World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland. Abstract 12389.
65. 65. Sadler BM, Piliero PJ, Preston SL, et al. Pharmacokinetic drug interaction between amprenavir and ritonavir in HW-seronegative subjects after multiple oral dosing. In: Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco, Calif. Abstract 77.
66. 66. Piscitelli S, Bechtel C, Sadler B, Falloon J. The addition of a second protease inhibitor eliminates amprenavir-efavirenz drug interactions and increases plasma amprenavir concentrations. In: Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco, Calif. Abstract 78.
67. 67. Yu L, Bridgers A, Polli J, et al. Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability. Pharm Res. 1999;16:1812-1817.
68. 68. McEvoy GK. (ed). AHFS Drug Information 2000. Bethesda, Md: American Society of Health-System Pharmacy, Inc.; 2000:3341-3343.